| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 0.92▼ | 0.92▼ | 0.92▼ | 0.95▼ | 1.05▼ |
| MA10 | 0.96▼ | 0.96▼ | 0.96▼ | 1.00▼ | 1.15▼ |
| MA20 | 0.98▼ | 0.98▼ | 0.99▼ | 1.08▼ | 1.23▼ |
| MA50 | 1.02▼ | 1.05▼ | 1.08▼ | 1.18▼ | 1.36▼ |
| MA100 | 1.11▼ | 1.14▼ | 1.19▼ | 1.28▼ | 1.52▼ |
| MA200 | 1.22▼ | 1.20▼ | 1.25▼ | 1.41▼ | 2.57▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.008▼ | -0.006▼ | -0.006▼ | -0.015▼ | -0.034▼ |
| RSI | 26.673▼ | 28.360▼ | 29.729▼ | 30.292▼ | 34.959▼ |
| STOCH | 0.971▼ | 0.971▼ | 3.163▼ | 14.858▼ | 13.112▼ |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -100.000▼ | -100.000▼ |
| CCI | -154.228▼ | -156.451▼ | -148.550▼ | -165.553▼ | -166.440▼ |
|
Monday, October 12, 2026 11:07 AM
Merck (NYSE:MRK) reported one year pivotal Phase 2b/3 data for remigromig in diabetic macular edema, showing non inferior efficacy to a leading anti VEGF therapy. The company described remigromig's ...
|
|
Friday, October 09, 2026 11:33 AM
Merck (NYSE:MRK) moved into focus as the healthcare sector firmed, with its oncology franchise, vaccines and pipeline shaping the day.
|
|
Thursday, October 08, 2026 10:36 AM
Merck & Co. (NYSE:MRK) gets a higher price target as quarterly revenue tops forecasts and Keytruda keeps driving its healthcare growth story.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 14/10/26 | 0.9201 | 0.9201 | 0.8903 | 0.8903 | 64,819 |
| 13/10/26 | 1.03 | 1.03 | 0.91 | 0.9249 | 175,201 |
| 12/10/26 | 0.98 | 1.03 | 0.98 | 1.01 | 107,800 |
| 09/10/26 | 0.93 | 1.00 | 0.93 | 0.9716 | 91,220 |
| 08/10/26 | 1.04 | 1.05 | 0.95 | 0.95 | 96,404 |
| 07/10/26 | 1.03 | 1.06 | 1.03 | 1.04 | 36,853 |
| 06/10/26 | 1.07 | 1.07 | 1.00 | 1.01 | 77,100 |
| 05/10/26 | 1.08 | 1.085 | 1.045 | 1.06 | 73,138 |
| 02/10/26 | 1.06 | 1.08 | 1.02 | 1.05 | 99,289 |
| 01/10/26 | 1.08 | 1.09 | 0.981 | 1.05 | 127,494 |
|
|
||||
|
|
||||
|
|